GANAB-Associated ADPKD Has a Generally Favorable Prognosis with Mild Kidney Disease and Preserved Renal Function
Patients with GANAB deletion mutations causing ADPKD typically experience mild polycystic kidney disease with limited chronic kidney disease progression, and kidney failure is rare or occurs only in older age. 1
Renal Prognosis
The 2025 KDIGO guidelines explicitly characterize ADPKD-GANAB as having:
- Mild PKD with limited CKD progression
- No kidney failure in most cases 1
- Low-to-moderate cyst numbers with limited kidney enlargement 1
Recent quantitative imaging data from 2026 supports this favorable renal outlook. Among 16 GANAB patients studied with advanced imaging biomarkers, no individual progressed to kidney failure during follow-up 2. The study revealed:
- Kidney involvement is heterogeneous (htTKV range 153-858 mL/m; total cyst number 3-42)
- Patients with kidney cyst number <20 had preserved kidney function with slower eGFR decline (median -1.68 mL/min/1.73 m²/year)
- Even those with ≥20 kidney cysts showed modest decline (-2.8 mL/min/1.73 m²/year) 2
Important Caveat: Phenotypic Variability Exists
While the typical presentation is mild, rare cases of severe, rapidly progressive disease have been documented. A 2025 case report described an 18-year-old with GANAB mutation classified as Mayo 1E (predicting rapid ESRD progression), challenging the assumption that all GANAB-associated disease is benign 3. This underscores that GANAB mutations can occasionally produce a severe phenotype requiring vigilant monitoring.
Hepatic Manifestations
Polycystic liver disease is the predominant feature and can be severe, sometimes requiring liver transplantation 1, 4, 5. The 2025 KDIGO guidelines note that GANAB can present as isolated ADPLD (autosomal dominant polycystic liver disease) 1. Quantitative imaging shows:
- Hepatic involvement is common and often more prominent than kidney disease
- Liver cyst numbers range from 22-219 with varying severity 2
- The phenotypic spectrum ranges from liver-predominant disease with minimal kidney involvement to more balanced kidney-liver disease 2
Extrarenal Complications
Intracranial Aneurysms
The risk of intracranial aneurysms (ICA) with GANAB mutations remains unclear according to KDIGO guidelines 1. However, recent data identified ICAs in 3 of 6 screened individuals (50%), including two from a family with known aneurysmal disease 2. This suggests screening may be warranted, particularly with positive family history.
Hypertension
Hypertension occurs in approximately 50% of GANAB patients 2, which is lower than typical PKD1/PKD2-associated ADPKD.
Critical Prognostic Distinction
The Mayo Imaging Classification (MIC) should NOT be used for GANAB-associated ADPKD 1. The MIC is validated only for PKD1 and PKD2 mutations, not minor genes like GANAB. Using MIC for GANAB patients may lead to inaccurate prognostic predictions.
Clinical Management Implications
Given the generally favorable renal prognosis:
- Kidney failure typically does not occur or develops only in advanced age 1
- Focus monitoring on hepatic complications, which may cause greater morbidity
- Screen for ICAs, especially with family history of aneurysmal disease
- Monitor blood pressure (present in ~50% of cases)
- Recognize that while most cases are mild, rare severe phenotypes exist requiring individualized risk stratification based on imaging findings (cyst burden, kidney volume) rather than genotype alone 2, 3
The phenotypic heterogeneity means that quantitative imaging biomarkers (htTKV, total cyst number) are more useful than genotype alone for predicting individual disease trajectory in GANAB-associated disease 2.